Key Highlights

  • Glaukos (NYSE:GKOS) surged 33.7% on October 29, 2026, the largest gain in a closing movers table covering S&P-adjacent stocks, according to a single published table.
  • Alnylam (NASDAQ:ALNY) fell 25.1% on the same day, the largest loss in the same closing movers table, which makes the pair the extremes of the session.
  • The cause of both moves was not verified in the material, and both figures come from one closing table, so they carry a single-source flag.
  • The pair offers a read-through for MedTech and RNAi biotech, but no company results, guidance or analyst notes were confirmed in the material reviewed here.

The Biggest Winner and Loser

Glaukos (NYSE:GKOS), a maker of eye-care devices and therapies, surged 33.7% on October 29, 2026. Alnylam (NASDAQ:ALNY), a pioneer in RNA interference medicines, fell 25.1%. Both appear in a single closing table of S&P-adjacent stocks, so the figures carry a single-source flag. Moves of 25% to 34% in one session are rare for companies of this size, and usually signal company-specific news such as results, guidance or a clinical or regulatory update. However, the cause was not verified for either company, so this article treats the moves as facts and the reasons as unknown. Neither company's results, guidance or analyst notes were confirmed in the material, so even the nature of the news behind each move is unknown. The table is described as covering the biggest winners and losers, which makes the pairing a market-wide snapshot.

Why Large Single-Day Moves Happen

In medtech and biotech, a single data point can change how investors value future revenue. For a device maker, a change in procedure volumes, reimbursement or product launches can shift Earnings forecasts. For an RNAi biotech, product sales, trial readouts or competitive data can do the same. A drop of 25.1% typically means expectations were high and something fell short, while a gain of 33.7% suggests results or guidance beat a low bar. Without the primary reports, those mechanisms remain hypotheses, and readers should confirm them in the company releases before drawing any conclusion. Moves like these also pull in Options and short positioning, which can magnify the first day's price change. A very large gain can therefore partly reflect forced buying, and a very large loss can reflect forced selling, in addition to the news itself.

Risks and What to Watch Next

Outsized moves can reverse, partly or fully, once more information is available. Following a 33.7% gain, Glaukos (NYSE:GKOS) faces the challenge of living up to a higher valuation, while Alnylam must show that its decline reflects a one-off reset. Peers in medtech and RNAi may also trade in sympathy. With a technology sell-off and a 10-year Yield near 4.94% to 4.98% in the background, risk appetite is uneven. Watch company releases, analyst notes and trading Volume in the next sessions, and treat the read-through as speculative until the cause is known. A related risk is liquidity, since fast moves can widen spreads and make it costly to trade. A closing table is also a snapshot and does not show what happened in premarket trading on October 30, 2026.

Where Things Stand

Glaukos (NYSE:GKOS) surged 33.7% on October 29, 2026. Alnylam (NASDAQ:ALNY) fell 25.1% the same day, but the reason for each move was not verified. The evidence is limited to one closing table, so the only firm conclusion is that both stocks repriced sharply on the same day. A balanced reading is that each reflects company-specific news that is still to be confirmed. The next catalyst is the primary company releases and analyst reactions. Both companies also sit in different corners of healthcare, so a shared cause is unlikely.